A Phase 1 interventional study of AG-013736 and AG-013736 in Advanced Solid Tumors, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-26.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AG-013736
Drug: AG-013736
Drug: AG-013736
Drug: AG-013736
Drug: AG-013736
Drug: AG-013736
Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
Axitinib continuous oral dosing (20 mg twice a day) in the fed state
Axitinib continuous oral dosing (5 mg twice a day) in the fed state
Axitinib continuous oral dosing (15 mg once a day) in the fed state
Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
Maximum Tolerated Dose (MTD)
MTD is defined as the dose level at which "no more than 1 of 6 participants experience dose-limiting toxicity (DLT) following de-escalation from the maximum administered dose (MAD)." DLT includes grade (Gr) 2 or greater gastrointestinal toxicities, Gr 3 anemia, nonhematological toxicities (excluding nausea, vomiting, and diarrhea) or Gr 4 neutropenia, thrombocytopenia and inability to resume axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
Time frame: Baseline up to Day 28
Maximum Observed Plasma Concentration (Cmax)
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hours (hrs) post-dose on Day (D) 1 and 15 of Cycle (C) 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Area Under the Curve From Time Zero to 12 Hours [AUC (0-12)]
AUC (0-12)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-12).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Apparent Oral Clearance (CL/F)
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Plasma Decay Half-Life (t1/2)
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 1 and 15 of Cycle 1 and Day 29 (Day 1 of Cycle 2); pre-dose on Day 43 (Day 15 of Cycle 2) and Day 57 (Day 1 of Cycle 3)
Maximum Observed Plasma Concentration (Cmax) in Fed State Versus Overnight Fasting
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Time to Reach Maximum Observed Plasma Concentration (Tmax) in Fed State Versus Overnight Fasting
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] in Fed State Versus Overnight Fasting
AUC (0-24)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-24).
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Apparent Oral Clearance (CL/F) in Fed State Versus Overnight Fasting
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
Plasma Decay Half-Life (t1/2) in Fed State Versus Overnight Fasting
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose, 0.5, 1, 2, 4, 8, and 12 hrs post-dose on Day 29 (Day 1 of Cycle 2) and Day 30 (Day 2 of Cycle 2)
| Milestone | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Started | 6 | 4 | 6 | 6 | 8 | 6 |
| Completed | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 6 | 4 | 6 | 5 | 8 | 6 |
| Withdrew: Adverse event | 2 | 3 | 0 | 2 | 0 | 1 |
| Withdrew: Progressive disease | 3 | 0 | 5 | 3 | 7 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Moved to rollover protocol | 1 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 1 | 0 |
MTD is defined as the dose level at which "no more than 1 of 6 participants experience dose-limiting toxicity (DLT) following de-escalation from the maximum administered dose (MAD)." DLT includes grade (Gr) 2 or greater gastrointestinal toxicities, Gr 3 anemia, nonhematological toxicities (excluding nausea, vomiting, and diarrhea) or Gr 4 neutropenia, thrombocytopenia and inability to resume axitinib (AG-013736) dosing within 14 days of stopping due to treatment related toxicity.
| mg BID | All Treated Participants |
|---|---|
| Maximum Tolerated Dose (MTD) | 5 |
| Nanogram/milliliter (ng/mL) | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Day 1 (n= 6, 4, 6, 5, 8, 6) | 144.48 ± 73.90 | 97.81 ± 89.96 | 20.71 ± 9.48 | 88.16 ± 84.93 | 22.21 ± 34.88 | 19.75 ± 17.95 |
| Day 15 (n= 6, 3, 5, 6, 6, 6) | 130.91 ± 60.23 | 94.75 ± 110.81 | 28.68 ± 8.33 | 67.08 ± 42.50 | 51.82 ± 31.21 | 52.24 ± 53.87 |
| Day 29 (n= 4, 3, 5, 5, 7, 6) | 76.25 ± 67.86 | 69.14 ± 103.14 | 26.44 ± 17.28 | 60.11 ± 103.76 | 43.28 ± 41.41 | 60.48 ± 29.10 |
| hr | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Day 1 (n= 6, 4, 6, 5, 8, 6) | 2.00 (1.00 to 4.00) | 4.04 (2.00 to 8.03) | 4.00 (1.00 to 4.08) | 2.05 (1.98 to 4.00) | 1.52 (0.50 to 4.00) | 1.01 (1.00 to 4.00) |
| Day 15 (n= 6, 3, 5, 6, 6, 6) | 3.00 (1.00 to 4.00) | 3.95 (2.08 to 4.05) | 2.00 (1.00 to 4.22) | 4.00 (2.00 to 11.83) | 1.01 (0.98 to 2.03) | 1.51 (0.98 to 4.00) |
| Day 29 (n= 4, 3, 5, 5, 7, 6) | 3.44 (0.00 to 4.03) | 4.13 (1.00 to 11.98) | 2.00 (1.00 to 4.00) | 3.50 (2.00 to 8.97) | 1.00 (0.50 to 4.02) | 2.01 (0.98 to 4.00) |
AUC (0-12)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-12).
| ng*hr/mL | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Day 1 (n= 6, 4, 6, 5, 8, 6) | 692.47 (363.89 to 1317.76) | 564.56 (100.47 to 3172.37) | 88.62 (60.05 to 130.80) | 473.26 (162.59 to 1377.58) | 68.73 (29.84 to 158.34) | 61.92 (19.33 to 198.31) |
| Day 15 (n= 6, 3, 5, 6, 6, 6) | 793.89 (372.39 to 1692.48) | 485.52 (15.97 to 14760.66) | 130.57 (77.24 to 220.72) | 380.56 (161.49 to 896.80) | 126.25 (50.65 to 314.70) | 218.05 (81.21 to 585.47) |
| Day 29 (n= 4, 3, 5, 5, 7, 6) | 456.53 (98.07 to 2125.11) | 441.50 (19.51 to 9989.18) | 144.13 (66.74 to 311.24) | 377.86 (104.98 to 1360.02) | 126.08 (55.72 to 285.29) | 253.45 (127.21 to 504.96) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
| Liter/hr (L/hr) | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Day 1 (n= 6, 4, 6, 5, 8, 6) | 19.80 (9.14 to 42.87) | 30.82 (5.00 to 189.99) | 53.17 (35.99 to 78.55) | 29.04 (10.34 to 81.59) | 71.82 (31.26 to 165.04) | 30.27 (8.95 to 102.37) |
| Day 15 (n= 6, 3, 5, 6, 6, 6) | 18.82 (8.90 to 39.78) | 32.69 (2.80 to 381.94) | 38.29 (22.65 to 64.73) | 30.61 (11.26 to 83.23) | 39.05 (15.38 to 99.13) | 22.93 (8.54 to 61.57) |
| Day 29 (n= 4, 2, 5, 5, 7, 6) | 27.32 (8.35 to 89.42) | 18.82 (0.00 to NA) | 34.69 (16.06 to 74.91) | 31.07 (7.11 to 135.74) | 38.51 (16.66 to 89.02) | 19.73 (9.90 to 39.31) |
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
| hr | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted |
|---|---|---|---|---|---|---|
| Day 1 (n= 6, 3, 5, 5, 5, 4) | 3.09 ± 1.00 | 3.29 ± 1.86 | 2.31 ± 0.64 | 3.08 ± 0.97 | 1.86 ± 0.44 | 3.77 ± 1.60 |
| Day 15 (n= 5, 3, 5, 4, 5, 6) | 5.20 ± 3.12 | 3.17 ± 1.71 | 2.22 ± 0.34 | 2.48 ± 0.68 | 2.01 ± 1.23 | 5.78 ± 6.33 |
| Day 29 (n= 3, 2, 5, 3, 6, 6) | 6.11 ± 4.23 | 3.94 ± 2.65 | 2.78 ± 0.80 | 2.16 ± 0.79 | 3.03 ± 0.74 | 3.33 ± 0.90 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
AUC (0-24)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-24).
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
No measurements were reported for this outcome.
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Treated Participants | — | 12/36 (33.3%) | 36/36 (100%) |
| Event | All Treated Participants |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/36 |
| ConvulsionNervous system disorders | 2/36 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/36 |
| HypertensionVascular disorders | 2/36 |
| DysphagiaGastrointestinal disorders | 1/36 |
| PainGeneral disorders | 1/36 |
| DehydrationMetabolism and nutrition disorders | 1/36 |
| Cardiac arrestCardiac disorders | 1/36 |
| Myocardial infarctionCardiac disorders | 1/36 |
| Supraventricular tachycardiaCardiac disorders | 1/36 |
| Event | All Treated Participants |
|---|---|
| HypertensionVascular disorders | 18/36 |
| Decreased appetiteMetabolism and nutrition disorders | 17/36 |
| FatigueGeneral disorders | 16/36 |
| NauseaGastrointestinal disorders | 14/36 |
| ConstipationGastrointestinal disorders | 12/36 |
| HeadacheNervous system disorders | 12/36 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 11/36 |
| VomitingGastrointestinal disorders | 10/36 |
| DiarrhoeaGastrointestinal disorders | 9/36 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/36 |
| Age Continuous(Years) | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.83 ± 8.75 | 58.50 ± 4.80 | 55.00 ± 7.27 | 56.00 ± 9.44 | 54.88 ± 7.95 | 64.17 ± 10.01 | 56.86 ± 8.53 |
| Sex: Female, Male(Participants) | Cohort 1: Axitinib (10 mg QD + 10 mg/20mg/30mg BID), Fed | Cohort 2: Axitinib 20 mg BID, Fed | Cohort 3: Axitinib 5 mg BID, Fed | Cohort 4: Axitinib 15 mg QD, Fed | Cohort 5: Axitinib 5 mg BID, Fasted | Cohort 6: Axitinib 2 mg + 5 mg BID, Fasted | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 2 | 2 | 5 | 3 | 20 |
| Male | 2 | 0 | 4 | 4 | 3 | 3 | 16 |
The record gives a start of Nov 2002, a primary completion of Jul 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 7 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib